AR and prostate cancer: Therefore, ABCC5 enhances the expression of phosphorylated P65, which in turn activates transcription by binding to the downstream AR promoter to enhance AR protein expression and pre-mRNA splicing, ultimately promoting enzalutamide resistance in prostate cancer.